Roquefort Therapeutics (LON:ROQ) Shares Up 4.6% – Time to Buy?

Roquefort Therapeutics plc (LON:ROQ) shares rose 4.6% during trading on Thursday . The stock traded as high as GBX 1.26 and last traded at GBX 1.26. Approximately 1,411,427 shares changed hands during mid-day trading, an increase of 101% from the average daily volume of 700,838 shares. The stock had previously closed at GBX 1.20.

Roquefort Therapeutics Stock Performance

The company’s fifty day moving average price is GBX 1.49 and its two-hundred day moving average price is GBX 1.65. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The firm has a market capitalization of £2.02 million, a PE ratio of -1.96 and a beta of 0.05.

Insiders Place Their Bets

In related news, insider Dr Darrin Disley purchased 5,000,000 shares of the business’s stock in a transaction on Friday, November 21st. The shares were bought at an average price of GBX 170 per share, with a total value of £8,500,000. 23.53% of the stock is currently owned by corporate insiders.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.